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Abstract
Background: Upper and lower respiratory tract infections (RTIs) account for a substantial portion of outpatient
antibiotic utilization. However, the pharmacodynamic activity of commonly used oral antibiotic regimens has not
been studied against clinically relevant pathogens. The objective of this study was to assess the probability of
achieving the requisite pharmacodynamic exposure for oral antibacterial regimens commonly prescribed for RTIs in
adults against bacterial isolates frequently involved in these processes (S. pneumoniae, H. influenzae, and
M. catharralis).
Methods: Using a 5000-subject Monte Carlo simulation, the cumulative fractions of response (CFR), (i.e.,
probabilities of achieving requisite pharmacodynamic targets) for the most commonly prescribed oral antibiotic
regimens, as determined by a structured survey of medical prescription patterns, were assessed against local
respiratory bacterial isolates from adults in São Paulo collected during the same time period. Minimal inhibitory
concentration (MIC) of 230 isolates of Streptococcus pneumoniae (103), Haemophilus influenzae (98), and Moraxella
catharralis (29) from a previous local surveillance were used.
Results: The most commonly prescribed antibiotic regimens were azithromycin 500 mg QD, amoxicillin 500 mg
TID, and levofloxacin 500 mg QD, accounting for 58% of the prescriptions. Varied doses of these agents, plus
gatifloxacin, amoxicillin-clavulanate, moxifloxacin, and cefaclor made up the remaining regimens. Utilizing
aggressive pharmacodynamic exposure targets, the only regimens to achieve greater than 90% CFR against all
three pathogens were amoxicillin/amoxicillin-clavulanate 500 mg TID (> 91%), gatifloxacin 400 mg QD (100%), and
moxifloxacin 400 mg QD (100%). Considering S. pneumoniae isolates alone, azithromycin 1000 mg QD also
achieved greater than 90% CFR (91.3%).
Conclusions: The only regimens to achieve high CFR against all three pathogen populations in both scenarios
were gatifloxacin 400 mg QD, moxifloxacin 400 mg QD, and amoxicillin-clavulanate 500 mg TID. These data
suggest the need for reconsideration of empiric antibiotic regimen selection among adult patients with RTIs in the
São Paulo area. Additionally, this type of study could be used to optimize prescribing patterns in specific regions in
light of emerging resistance.
Background
Mortality due to infections represents approximately 85%
of all deaths worldwide, and community acquired ones
are highly prevalent [1]. Among these, respiratory tract
infections (RTIs) are among the most common causes of
morbidity in the community worldwide. Streptococcus
pneumoniae is the most common bacterial cause of
upper and lower respiratory tract community infections,
particularly pneumonia [2]. Additionally, it is one of the
most frequent causative agents in meningitis and bactere-
mia, as well as the main cause of upper respiratory non
invasive infections, such as otitis media and sinusitis
[3-5]. Infections caused by S. pneumoniae can occur in
all age groups, but are more prevalent in children and the
elderly [2,6,7], thus recommendations for vaccination in
these age groups. Furthermore, other bacterial pathogens
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mophilus influenzae is recognized as a frequent cause of
acute sinusitis in children and adults as well as pneumo-
nia in developing countries; these respiratory infections
are caused most commonly by non-type b strains. Finally,
although a less frequent cause of respiratory tract infec-
tions, Moraxella catarrhalis m a yb ea s s o c i a t e dw i t h
diverse disease conditions, such as laryngitis in adults [8].
It has also been associated with acute exacerbations of
chronic obstructive pulmonary disease (COPD), pneumo-
nia in the elderly, and hospital respiratory infections [8].
Since nearly all respiratory infections are treated empiri-
cally, knowledge of antibacterial resistance determined
periodically with contemporary isolates is valuable.
However, the susceptibility pattern alone might be insuf-
ficient to guide optimal antimicrobial therapy, since most
of the community acquired infections present a risk of
resistance development to a first line antimicrobial drug
[1], leading to changes in susceptibility patterns of com-
monly used agents over time. This resistance pattern mod-
ification over time may limit the utility of regulatory
clinical studies conducted decades ago. Consequently, pre-
scription patterns may need to evolve, with some com-
pounds requiring dosing adjustments or new formulations
in order to maintain efficacy. The increasing burden of
antimicrobial resistance coupled with the relative drought
on the antimicrobial developmental pipeline has urged for
strategies to reduce antibiotic consumption and to maxi-
mize treatment approaches [9].
In this setting, pharmacodynamic analysis of estab-
lished antimicrobial therapies may be a useful approach
to predict the successful eradication of specific pathogens
causing infection at specific sites [10,11]. Additionally,
pharmacodynamic modeling has been an important con-
sideration in the development of guidelines for treatment
of infections, including acute otitis media and sinusitis
[12-14]. For beta-lactams, the time for which free drug
concentrations remains above minimum inhibitory con-
centration (MIC) as a function of the dosing interval (fT
> MIC) is well established to be the pharmacodynamic
index predictive of successful response [10]. For fluoro-
quinolones, the maximum concentration to MIC ratio
(Cmax/MIC) or area under the curve to MIC ratio
(AUC/MIC) are the pharmacodynamic indices predictive
of success [11]. Lastly, for azithromycin, the AUC/MIC
appears to be the pharmacodynamic ratio predictive of
success [11], due to its long half-life, but clinical studies
to demonstrate exposure-response relationships are
limited.
The objective of this study was to assess the probability
of achieving the requisite pharmacodynamic exposure for
oral antibacterial regimens commonly prescribed for
respiratory infections in adults against bacterial isolates
frequently involved in these processes (S. pneumoniae, H.
influenzae, and M. catharralis) in Sao Paulo, Brazil.
Methods
Definition of Commonly Prescribed Antimicrobials
A 2006 database (INTE, National Index of Therapeutics
and Diseases) from a commercial prescription survey (IMS
Health Brasil) was used to determine the antimicrobial
prescription pattern of physicians within the city of São
Paulo for respiratory tract infections (upper and lower, all
inclusive) in adults from January to December 2006. The
database is composed of structured prescription data col-
lected through a survey performed with a stratified and
representative sample of 399 physicians, divided by city
geographical regions and specialty (16 specialties). The
survey is conducted every trimester through a structured
questionnaire to allow for data capture by each doctor and
specific medical visits, patient demographics, week sur-
veyed, type of disease, dose and amount prescribed
(volume, formulation and dosage per diagnosis).
For the current study, we determined the mean dose
prescribed per day for the most frequent antimicrobials
based on total number of mentions (in thousands) for the
specific product, number of mentions (in thousands) per
dosage, and percent participation of each dosage in formu-
lary for the last 12 months. Antimicrobial drugs prescribed
in less than 1% of the population, such as cefuroxime, clar-
ithromycin, and intramuscular ceftriaxone were not
included in final analysis.
Microbiological Data
Microbiological data was extrapolated from a regional
2003-2004 surveillance based on routine bacterial isolates
collected from four laboratories located in São Paulo. The
isolates were a subset of the referred study, comprising
exclusively outpatients older than 16 years of age with
respiratory isolates, i.e., sampled from middle ear fluid,
sinus fluid, throat swab, sputum, broncho-alveolar lavage
(BAL), or nasopharyngeal swab from the referred period.
All S. pneumoniae, H. influenzae,a n dM. catharralis iso-
lates were subjected to MIC determination by microdilu-
tion assays according to the respective year’sC l i n i c a l
Laboratory Standard Institute (CLSI) recommendations
[15].
Pharmacokinetics
For the most commonly prescribed oral antibiotics, phar-
macokinetic data were obtained from previously pub-
lished studies in healthy volunteers [16-20]. For studies
to be considered, they had to be conducted in at least 10
healthy volunteers, described the assay used to determine
drug concentrations and present mean and standard
deviation results for the total body clearance in liters per
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ment (Vc), absorption rate constant (K01) and other per-
tinent pharmacokinetic parameters. For amoxicillin, CL
and Vc estimates were reported in L/kg/hr and L/kg,
r e s p e c t i v e l y ,s oap a t i e n tp opulation with weight of
70 +/- 5 kg was used to scale these parameters during the
Monte Carlo simulation. Because a published report with
the above characteristics was not identified for cefaclor,
we modeled the pharmacokinetics (Winnonlin, Version
5.3) based on a study that provided detailed concentra-
tion-time points for each subject [21] and used the
model to generate parameters to be applied in the Monte
Carlo simulation analyses. As body weight for individual
patients was not reported in the cefaclor study, our Win-
NonLin derived estimates for CL and Vc were in L/hr
and L, respectively, and it was not necessary to apply
body weight during the Monte Carlo simulation. For the
fluoroquinolones and azithromycin, clearance controlled
for bioavailability (CL_F) was extrapolated from the phar-
macokinetic studies.
Simulated distributions for all pharmacokinetic para-
meters were consistent with log-Gaussian distributions
in accordance with the data inputted into the models
(Table 1).
Pharmacodynamic Analyses
A 5000-patient Monte Carlo simulation (Crystal Ball,
2000) was conducted to calculate estimates of fT>M I C
or the AUC/MIC ratio for each antibiotic regimen/bacter-
ial population combination. The dosage regimens chosen
were based on the most common regimens prescribed
according to the survey database. Pharmacodynamic expo-
sures, as measured by fT > MIC, were simulated for oral
regimens of amoxicillin 500 mg three times daily (TID)
and 875 mg twice daily (BID), amoxicillin-clavulanate 500/
125 mg q8h and 875/125 mg BID, and cefaclor 500 mg,
750 mg, 250 mg, and 375 mg BID against all pathogens
(except for cefaclor, only simulated against S. pneumo-
niae). For amoxicillin, amoxicillin-clavulanate, and cefa-
clor, a two-compartment pharmacokinetic model with lag
time was used to simulate steady-state concentration time
profiles. Pharmacodynamic exposures, as measured by free
drug AUC/MIC ratio, were simulated for levofloxacin 500
mg and 250 mg once daily (QD), gatifloxacin 400 mg QD,
moxifloxacin 400 mg QD (all pathogens). Pharmacody-
namic exposures, as measured by the total drug 24-hours
AUC/MIC ratio, were modeled for azithromycin 500 mg
and 1000 mg QD (all pathogens). For the fluoroquinolones
and for azithromycin, AUC was calculated as the daily
dose divided by CL_F.
Values for fT > MIC and AUC/MIC were plotted on
frequency curves for further analysis. The probabilities of
obtaining a fT > MIC of 20%, 30%, 40%, 50%, 60%, 70%,
80%, 90%, and 100% were calculated for all the beta-
lactams at increasing MICs in doubling dilutions. For
comparative purposes, two scenarios were built for beta-
lactams and for azithromycin: 1) aggressive pharmacody-
namic breakpoints were defined as requiring 50% fT>
MIC for all beta-lactams and total AUC/MIC ≥ 25 [22]
for azithromycin; 2) conservative pharmacodynamic
breakpoints were defined as requiring 30% fT>M I Cf o r
all beta-lactams and total AUC/MIC ≥ 10 [23] for azi-
thromycin. In both scenarios, the probability of achieving
a fAUC/MIC ratio of at least 33.7 was calculated for
fluoroquinolones [24]. These probabilities of target
attainment were applied to the MIC distributions for the
above pathogens to calculate the cumulative fraction of
response (CFR).
Results
Most commonly prescribed antimicrobial agents
Table 2 provides the antimicrobials and dosing regimens
most frequently prescribed for community RTIs (exclud-
ing pediatric formulations) and the relative frequency of
prescription for each presentation.
Microbiology
Table 3 shows MIC distributions for 230 total isolates of
S. pneumoniae (103), H. influenzae (98), and M. cathar-
ralis (29) from a local prevalence study. According to
present CLSI criteria [15], S. pneumoniae showed 100%
susceptibility to penicillin, 91.3%to azithromycin, and
100%to the fluoroquinolones (levo, moxi, and gatifloxa-
cin). As for H. influenzae, susceptibility to penicillin was
87.7% and 100% to azithromycin. M. catharralis showed
100% of MICs to amoxicillin above 1 mcg/mL.
Pharmacokinetic parameters
Table 1 shows a summary of pharmacokinetic parameters
for antimicrobials used in the Monte Carlo simulations.
Pharmacodynamic target attainment
Table 4 lists CFR results using the aggressive pharmacody-
namic exposure targets (scenario 1) for each prescribed
antimicrobial regimen against each of the outpatient
respiratory bacteria. Table 5 lists CFR results using the
conservative pharmacodynamic exposure targets (scenario
2) for each prescribed antimicrobial regimen against each
of the outpatient respiratory bacteria.
Discussion
The present study evaluated the probability of achieving
pharmacodynamic exposures for the most frequently
prescribed oral antimicrobial regimens used to treat
respiratory infections in adults in the São Paulo region
against the most commonly isolated bacterial pathogens.
This is the first multidrug comparison of oral antibiotics
against clinically relevant RTI pathogens in adults. The
Kiffer and Pignatari BMC Infectious Diseases 2011, 11:286
http://www.biomedcentral.com/1471-2334/11/286
Page 3 of 9Table 1 Summary of pharmacokinetic parameters for antimicrobials used in the Monte Carlo simulation
Pharmacokinetic Parameter (mean ± SD)
Antibiotic CLT (L/hr) Vc (L) Fraction unbound (%)* Intercompartment Rate Constants (h
-1) Absorption Rate Constant (h
-1)
K12 K21 K01
Amoxicillin ± clavulanate 22.2677 ± 5.8091 14.0622 ± 5.5932 80 ± 2 1.77 ± 2.27 1.91 ± 1.12 0.93 ± 0.49
Cefaclor 43.1513 ± 13.0045 29.3195 ± 8.3441 75 ± 5 0.45 ± 0.12 1.15 ± 0.35 2.61 ± 0.78
CL_F (L/hr)
Azithromycin 122 ± 33 ——
Levofloxacin 10.5 ± 1.48 — 62-76
Gatifloxacin 12.54 ± 1.27 — 78-82
Moxifloxacin 14.9 ± 1.18 — 49.5-70
* Fraction unbound estimates simulated as a mean (SD) Gaussian distribution for amoxicillin, co-amoxiclav, and cefaclor. Estimates simulated as a range for the FQ and azithromycin, where each value in the range
has an equal likelihood of occurring.
CLT = total body clearance reported from 2-compartment model; Vc = volume of the central compartment reported from 2-compartment model; K12 = intercompartment rate constant between first and second







































































































9antimicrobial regimens simulated were extracted from a
commercial database survey applied to a representative
medical population of the São Paulo region in 2006.
Additionally, the infectious pathogens (S. pneumoniae,
H. influenzae,a n dM. catharralis)w e r ei s o l a t e df r o m
the same geographical area (city of São Paulo) within a
similar, albeit slightly earlier, time period (2003-2004).
The pathogens were part of a previous local surveillance
study collected from four (4) centers located in São
Paulo during a two (2) year study. Only isolates from
adult (> 16 years-old) outpatients with respiratory infec-
tions (sampled from middle ear fluid, sinus fluid, throat
Table 2 Most frequently prescribed antimicrobial regimens for community RTIs with relative prescription frequency
ANTIMICROBIAL Prescribed Dosing Regimen % Relative prescription frequency per drug formulation
AZITHROMICIN 500 mg QD 27.4%
AMOXICILLIN 500 mg TID 15.4%
LEVOFLOXACIN 500 mg QD 14.7%
AMOXICILLIN 875 mg BID 6.5%
GATIFLOXACIN 400 mg QD 6.3%
AZITHROMICIN 1000 mg QD 6.0%
AMOXICILLIN-CLAVULANIC ACID 875 mg BID 5.8%
LEVOFLOXACIN 250 mg QD 5.1%
AMOXICILLIN-CLAVULANIC ACID 500 mg TID 4.7%
MOXIFLOXACIN 400 mg QD 3.5%
CEFACLOR 500 mg BID 0.8%
CEFACLOR 750 mg BID 0.8%
CEFACLOR 250 mg BID 0.5%
CEFACLOR 375 mg BID 0.4%
Table 3 MIC distributions for S. pneumoniae, H. influenza, and M. catharralis included in the study
Percentage (%) of bacteria at each MIC value (mg/L)
Bacterial group (n) and antimicrobial 0.008 0.016 0.032 0.06 0.125 0.25 0.5 1 2 4 8 16 32 > 32
S. pneumoniae (103)
Penicillin 2.9 27.2 24.3 18.4 7.8 5.8 1.0 9.7 2.9 0.0 0.0 0.0 0.0 0.0
Amoxicillin 0.0 1.0 64.1 17.5 2.9 1.9 1.0 1.0 7.8 1.9 1.0 0.0 0.0 0.0
Co-amoxiclav 0.0 1.0 64.1 17.5 2.9 1.9 1.0 1.0 7.8 1.9 1.0 0.0 0.0 0.0
Cefaclor 0.0 0.9 0.0 1.9 4.6 36.1 37.0 5.6 1.9 1.9 0.9 0.9 5.6 2.8
Azithromycin 0.0 0.0 7.8 63.1 20.4 0.0 0.0 0.0 0.0 0.0 1.9 1.0 0.0 5.8
Levofloxacin 0.0 0.0 0.0 0.0 0.0 0.0 14.6 80.6 4.9 0.0 0.0 0.0 0.0 0.0
Gatifloxacin 0.0 0.0 0.0 0.0 2.9 79.6 17.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Moxifloxacin 0.0 0.0 0.0 10.7 71.8 17.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
H. influenzae (98)
Penicillin 0.0 0.0 0.0 0.0 55.1 16.3 11.2 5.1 0.0 0.0 3.1 4.1 5.1 0.0
Amoxicillin 0.0 0.0 0.0 0.0 7.1 51.0 19.4 8.2 2.0 3.1 0.0 0.0 9.2 0.0
Co-amoxiclav 0.0 0.0 0.0 0.0 9.2 44.9 30.6 12.2 3.1 0.0 0.0 0.0 0.0 0.0
Azithromycin 0.0 0.0 0.0 0.0 3.1 5.1 24.5 44.9 21.4 1.0 0.0 0.0 0.0 0.0
Levofloxacin 30.6 66.3 2.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Gatifloxacin 0.0 96.9 2.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Moxifloxacin 11.2 67.3 18.4 2.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
M. catharralis (29)
Amoxicillin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.9 6.9 13.8 24.1 27.6 20.7 0.0
Co-amoxiclav 0.0 0.0 0.0 0.0 51.7 41.4 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Azithromycin 0.0 0.0 0.0 96.6 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Levofloxacin 0.0 0.0 93.1 6.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Gatifloxacin 0.0 20.7 75.9 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Moxifloxacin 0.0 0.0 34.5 65.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
MIC = minimum inhibitory concentration; Co-amoxiclav = amoxillin-clavulanate
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Page 5 of 9swab, sputum, broncho-alveolar lavage (BAL), or naso-
pharyngeal swab) were included in the present analysis.
Since nearly all RTIs are treated empirically, knowledge
of antibacterial resistance determined periodically is
valuable. In this study, the bacterial isolates included
were in general representa t i v ef o rR T I si nt h ea d u l t
population during years 2003 and 2004. The total 230
isolates were apparently significant for this population
[25,26], with less M. catharralis isolates.
We detected that different formulations (i.e. doses) of
azithromycin, amoxicillin, and levofloxacin accounted for
85.7% of the top prescribed respiratory drugs. Azithro-
mycin 500 mg QD ranked first regimen (27.4%) for RTIs
in the 2006 period. We did not detect high dose amoxi-
cillin and/or co-amoxiclav (1000 mg TID) in the
prescription survey. It is important to notice that both
high dose beta-lactams are present in recommendations
issued by the Infectious Disease Society of America
(IDSA)/American Thoracic Society (ATS) for community
acquired pneumonia [27], but the survey was conducted
prior to the release of these recommendations. It should
also be noted that, although the prescribing pattern in
São Paulo only has local representation, prescription sur-
veys may be useful to guide future pharmacodynamic
modeling in diverse environments.
As for the pharmacodynamic targets adopted, we do
acknowledge the existence of a large discrepancy refer-
ring to what should be considered an aggressive manage-
ment strategy, particularly for beta-lactams. Although
bactericidal targets for beta-lactams have been widely
Table 4 Scenario 1: Cumulative fraction of response (CFR) for achieving aggressive* pharmacodynamic indice
exposures for prescribed antimicrobial regimens against outpatient respiratory isolates
ANTIBIOTIC Dosing Regimen S. pneumoniae H. influenzae M. catharralis
AMOXICILLIN 875 mg BID 88.2% 69.1% 4.8%
AMOXICILLIN 500 mg TID 91.2% 82.1% 7.4%
AMOXICILLIN-CLAVULANIC ACID 875 mg BID 88.2% 76.1% 88.8%
AMOXICILLIN-CLAVULANIC ACID 500 mg TID 91.2% 91.9% 98.5%
AZITHROMICIN 1000 mg QD 91.3% 46.8% 99.6%
AZITHROMICIN 500 mg QD 76.50% 7.8% 81.4%
CEFACLOR 750 mg BID 17.0% ––
CEFACLOR 500 mg BID 9.8% ––
CEFACLOR 375 mg BID 6.1% ––
CEFACLOR 250 mg BID 2.6% ––
GATIFLOXACIN 400 mg QD 100.0% 100.0% 100.0%
LEVOFLOXACIN 500 mg QD 51.4% 100.0% 100.0%
LEVOFLOXACIN 250 mg QD 6.6% 100.0% 100.0%
MOXIFLOXACIN 400 mg QD 100.0% 100.0% 100.0%
* Beta-lactams = 50% fT > MIC; Azithro = total AUC/MIC ≥ 25; Fluoroquinolones fAUC/MIC ≥ 33.7
Table 5 Scenario 2: Cumulative fraction of response (CFR) for achieving conservative* pharmacodynamic indice
exposures for prescribed antimicrobial regimens against outpatient respiratory isolates
ANTIBIOTIC Dosing Regimen S. pneumoniae H. influenzae M. catharralis
AMOXICILLIN 875 mg BID 95.5% 86.9% 14.6%
AMOXICILLIN 500 mg TID 96.3% 87.8% 14.8%
AMOXICILLIN-CLAVULANIC ACID 875 mg BID 95.5% 97.8% 99.7%
AMOXICILLIN-CLAVULANIC ACID 500 mg TID 96.3% 99.4% 100.0%
AZITHROMICIN 1000 mg QD 91.8% 99.2% 100.0%
AZITHROMICIN 500 mg QD 91.3% 67.9% 99.9%
CEFACLOR 750 mg BID 58.6% ––
CEFACLOR 500 mg BID 45.5% ––
CEFACLOR 375 mg BID 35.4% ––
CEFACLOR 250 mg BID 22.0% ––
GATIFLOXACIN 400 mg QD 100.0% 100.0% 100.0%
LEVOFLOXACIN 500 mg QD 51.4% 100.0% 100.0%
LEVOFLOXACIN 250 mg QD 6.6% 100.0% 100.0%
MOXIFLOXACIN 400 mg QD 100.0% 100.0% 100.0%
* Beta-lactams = 30% fT > MIC; Azithro = total AUC/MIC ≥ 10; Fluoroquinolones fAUC/MIC ≥ 33.7
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were modeled. However, the respective figure for various
T > MIC exposure targets was not included in the pre-
sent paper for better clarity. Also, it is noteworthy to
mention that prescription data was from 2006 and micro-
biological data from was from 2003-2004. Although there
may have been changes in both resistance and prescrip-
tion patterns over time, periods were close enough in
order to achieve the main purpose of the study, which
was to shed light on commonly prescribed oral agents
and their potential activity or lack thereof. Additionally,
the study could serve as a model to be used within areas
with different prescribing habits.
Based on the premises that antimicrobial survey data
was indicative of prescription and usage, and that micro-
biological data was representative of RTIs in adults, both
in similar period and area, simulation was performed
using previously published pharmacodynamic targets. Two
hypothetic scenarios were used: scenario 1, with more
aggressive pharmacodynamic exposure targets for beta-
lactams (50% fT > MIC) and for azithromycin (total AUC/
MIC ≥ 25); and scenario 2, with more conservative targets
(Beta-lactams = 30% fT > MIC; azithromycin = total
AUC/MIC ≥ 10). Although appropriate pharmacodynamic
targets for azithromycin are not well established, the dif-
ferent scenarios presented aimed at partially addressing
this issue.
In scenario 1, as shown in table 4, only gatifloxacin
400 mg QD and moxifloxacin 400 mg QD achieved 100%
CFR against all three pathogens, while amoxicillin-clavu-
lanate (500/125 mg TID) and azithromycin 1000 mg QD
both achieved above 90%. All other antimicrobial regi-
mens achieved below 90% CFR against at least one
pathogen in scenario 1. Scenario 2, shown in table 5, with
am o r ec o n s e r v a t i v ep h a r m a c odynamic profile, demon-
strated that CFR for gatifloxacin 400 mg QD and moxi-
floxacin 400 mg QD were again 100% against all
pathogens. However, this time, amoxicillin-clavulanate in
both dosing formulations (500/125 mg TID and 875/125
mg BID) achieved above 90% CFR for all pathogens. All
other antimicrobial regimens achieved below 90% CFR
for at least one pathogen in scenario 2. It is relevant,
though, that azithromycin 1000 mg QD achieved high
CFR against all pathogens in this scenario, but azithor-
mycin 500 mg QD had a worst performance against
H. influenzae (67.9%).
Also of importance, levofloxacin 500 mg QD did not
perform as well as gatifloxacin and moxifloxacin against S.
pneumoniae, with a CFR of 51.4%. It has been previously
demonstrated that gatifloxacin or moxifloxacin have a
higher probability of achieving the AUC/MIC target than
does levofloxacin [28]. Although the present study did not
evaluate the levofloxacin 750 mg QD regimen, it has also
been established that levofloxacin administered at a dose
of 750 mg QD has a higher CFR and improved bacteriolo-
gical outcome against S. pneumoniae than the 500 mg QD
regimen [29,30]. It seems that for the environment stu-
died, the levofloxacin 500 mg QD regimen is not adequate
against S. pneumoniae. However, it is important to note
that most studies [28-31] demonstrated a poor probability
of target attainment for the levofloxacin 500 mg QD regi-
men when MICs are 1 mcg/ml or more. Most of the iso-
lates evaluated (80.6%) had MICs of 1 mcg/mL. However,
another possible explanation for the low CFR found for
levofloxacin lies on the clearance utilized to simulate its
exposure. The present study used healthy volunteer data
and it has been previously shown that levofloxacin clear-
ance is reduced in patients compared with healthy volun-
teers, leading to higher AUCs in the patient population
[28,29].
Pichichero et al [32] developed a similar strategy, while
assessing the probability of achieving requisite pharmaco-
dynamic exposures through Monte Carlo simulation for
commonly used antimicrobials to treat children with bac-
terial RTIs against contemporary H. influenzae. A relevant
conclusion in their article was that cefpodoxime, ceftibu-
ten, and amoxicillin/clavulanic acid were the most likely
antimicrobials to achieve optimal in vivo exposures in chil-
dren with H. influenzae infections. In the present study we
aimed at the adult population and their commonly pre-
scribed antimicrobials. Also, the regimens were simulated
against the most frequent bacterial pathogens causing
RTIs, i.e. S. pneumoniae, H. influenzae,a n dM. catharralis.
The use of the IMS database seems significant from the
clinical viewpoint, since it is an alternative to obtain an
estimation of population antimicrobial usage patterns.
Nevertheless, it should not be understood as a definite
result, since prescription patterns vary from place to place
and do not necessarily represent usage. However, it could
apparently be used as a possible indication of significant
prescription data within specific environments.
Conclusion
Overall, the fluoroquinolones, gatifloxacin and moxiflox-
acin, attained the highest CFR (100%) against all patho-
gens studied. Across all pathogens, co-amoxiclav 500 mg
TID and 875 mg BID and azithromycin 1000 mg QD (in
the conservative scenario) were above 90% also. Both
cefaclor and low dose levofloxacin (250 mg QD) should
be avoided to treat RTIs in this environment, due to their
low performance against major RTI pathogens (and
against S. pneumoniae for cefaclor). The present data
suggest the need for reconsideration of empiric antibiotic
regimen selection among adult patients with respiratory
tract infections in the São Paulo area. It is our under-
standing that this type of study can be used to optimize
prescribing patterns in specific regions in light of emer-
ging resistance.
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